Discover how NGS-based pharmacogenomics improves variant detection and patient safety. Join our webinar on March 10th at 2pm ...

[more than 13% of patients with advanced NSCLC and an aSV] "would have experienced a meaningful delay of several weeks or more if RNA-NGS and DNA-NGS had been performed sequentially rather than ...

Acute Myeloid Leukemia is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally.​ -With relapse rates as high as 50%, routine measurable residual disease (MRD) ...

IDT's suite of NGS innovations aim to tackle longstanding bottlenecks in library preparation, targeted enrichment, and whole genome analysis.

Criteria for NGS testing in MNs can reduce unnecessary tests, saving costs without affecting patient care quality. Six approval and six cancellation criteria guide appropriate NGS use, focusing on ...

This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted ...

Market Outlook and Growth TrajectoryThe global next generation sequencing market is poised to experience robust expansion, registering an estimated growth rate of around 15% over the next five years.

Today, OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of ...

Although next-generation sequencing (NGS) keeps giving—exploring the human genome and revolutionizing our knowledge of health and disease—it needs to take a little, too. At the very least, NGS ...

Even the most straightforward next-generation sequencing (NGS) experiments can be expensive and time-consuming. Thus, it’s a good idea to test your workflow on a few samples to make sure you’ll get ...